Rights issue enables market expansion

The Board of Directors and the CEO of Phase Holographic Imaging PHI AB (publ), corporate identity number 556542-7811, hereby submit Interim Report 1 for the fiscal year 2018/19.

Read more

Kallelse till årsstämma i Phase Holographic Imaging PHI (publ)

Aktieägarna i Phase Holographic Imaging PHI AB (publ), 556542-7811, kallas härmed till årsstämma onsdagen den 26 september 2018 kl. 17.00 i bolagets lokaler, Scheelevägen 22 i Lund.

Read more

Kommuniké från extra bolagsstämma i Phase Holographic Imaging PHI AB (publ)

Igår, den 18 juni 2018, hölls extra bolagsstämma i Phase Holographic Imaging PHI AB (publ). Stämman röstande enhälligt för föreslagna beslut gällande nyemission.

Read more

PHI and BioSpherix sign co-marketing agreement

Phase Holographic Imaging (PHI) and BioSpherix recently signed a collaboration agreement aiming to co-market the companies’ complementary product lines. BioSpherix, NY USA, manufactures and markets advanced cell incubators.

Read more

Notice of Extraordinary General Meeting in Phase Holographic Imaging PHI AB (publ)

Notice to the shareholders in Phase Holographic Imaging AB (publ), 556542-7811, to attend an Extraordinary General Meeting on Monday June 18 at 06.00 PM (18.00) at PHI’s office, Scheelevägen 22, Lund.

Read more

Decision on rights issue for continued growth, establishment of sales organization and commercial break-through

The Board of directors of Phase Holographic Imaging PHI AB (publ) (”PHI”) has decided to conduct a rights issue of units, which is subject to approval on Extraordinary General Meeting, that can provide the company a total of SEK 64.6 million at the most prior to issuing costs.

Read more

PHI increase sales in fourth quarter, as well

PHI hereby announces that net sales during the fourth and final fiscal quarter of 2017/18 amounted to 2.2 (1.2) MSEK, resulting in that the company saleswise achieves its best quarter ever for the second consecutive quarter.

Read more

PHI and world-leading research institute evaluate quantitative imaging of living tumor cells

QIMR Berghofer Medical Research Institute in Brisbane and PHI have entered an evaluation agreement to explore the use of live cell time-lapse cytometry based on quantitative phase microscopy to determine the impact of hypoxic microenvironment on cellular motility and metastatic potential in solid cancers.

Read more

University of California, San Francisco and Phase Holographic Imaging establish Center of Excellence

University of California, San Francisco (UCSF) and Phase Holographic Imaging (PHI) have agreed to expand their on-going collaboration and establish a regional Holographic Imaging Cytometry Center of Excellence, located at the UCSF Helen Diller Family Comprehensive Cancer Center.

Read more

Novel HoloMonitor method identifies tumor creating cancer cells

Using HoloMonitor®, researchers at Harvard Medical School and Boston Children’s Hospital have developed a novel non-invasive method for distinguishing between active and dormant cancer cells.

Read more